摘要
目的探讨舒利迭治疗慢性阻塞性肺病稳定期的临床疗效。方法选择我院2009年1月～2010年3月慢性阻塞性肺病稳定期患者68例,随机分为对照组和治疗组。对照组34例予常规治疗,治疗组34例通过吸入装置准纳器沙美特罗/丙酸氟替卡松50/250 ug:1喷,Bid;治疗3个月并随访1年。比较两组肺功能、健康相关生活质量评分变化情况、1年内再入院情况。结果治疗组3个月、1年肺功能、生活质量评分、1年内住院次数与对照组比较,有明显改善,差异有统计学意义,P<0.05;治疗组1年FEV1减退率为-0.11±0.15 L,对照组为0.16±0.10 L,差异有统计学意义,P<0.001。结论舒利迭吸入治疗慢性阻塞性肺病稳定期患者能延缓肺功能下降速度,提高健康相关生活质量,降低1年内再入院的危险。
Objective To study the clinical effect of Seretide in stable stage of chronic obstructive pulmonary disease （COPD）. Methods 68 patients in stable stage of COPD from January 2009 to March 2010 are randomly divided into control group and treatment group. 34 patients in control group are given foundational treatment, while 34 patients in treatment group are given Salmeterol/Fluticasone 50/250 1 bid via the inhaler Discus during the next 3 month and are followed up for 1 year. Chauges of pulmonary function and health - related quality of life score, and admissions to hospital in 1 year of the two groups are compared. Results Pulmonary function in 3 months and 1 year, life quality score and the number of admission to hospital in treatment grnup are improved significantly, which has statistically significant difference, P 〈0. 05 compared with the control group. FEV1 decline rate of treatment group in 1 year is -0. 11 ± 0. 15 L, which also has statistically significant difference compared with the control group with 0. 16 ±0. 10 L, P 〈0. 001. Conclusion Seretide can slow the decline rate of lung function, improve health-related qnality of life, and reduce the risk of readmission to hospital in 1 year of the patients in the stable stage of chronic obstructive pulmonary disease.
出处
《临床肺科杂志》
2012年第1期62-64,共3页
Journal of Clinical Pulmonary Medicine
关键词
舒利迭
慢性阻塞性肺疾病
肺功能
生活质量评分
1年内住院次数
seretide
chronic obstructive pulmonary disease
pulmonary function
health-related quality of life score
admissions to hospital in 1 year
